# HOOKIPA Pharma Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/HOOKIPA Pharma Inc.). ## Overview HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing immunotherapies and vaccine candidates built on its proprietary replicating and non-replicating viral vector technologies. The company has not commercialized any products and currently generates revenue only from collaboration and licensing agreements, primarily with Gilead and Roche. ## Products & services • Clinical-stage immunotherapy and vaccine product candidates • Replicating and non-replicating viral vector technology platforms • HBV and HIV vaccine collaboration programs with Gilead • Oncology and other serious-disease programs under development • Research collaboration and license agreements - **Vaccine and immunotherapy candidates** (0%) — Preclinical and clinical product candidates designed to prevent or treat serious diseases using viral-vector-based immunology. - **Technology platforms** (0%) — Replicating and non-replicating viral vector technologies used to create new product candidates and partnership opportunities. - **Collaboration and licensing revenue** (100%) — Upfront, milestone, initiation and reimbursement revenue from partner agreements such as Gilead and Roche. - Clinical-stage immunotherapy and vaccine product candidates - Replicating and non-replicating viral vector technology platforms - HBV and HIV vaccine collaboration programs with Gilead - Oncology and other serious-disease programs under development - Research collaboration and license agreements ## Customers HOOKIPA does not sell commercial products today; its customers are collaboration partners that fund research and development through licensing and development agreements. The company’s end-market focus is on patients with HBV, HIV, cancer and other serious diseases, but monetization currently comes from large pharmaceutical partners rather than direct product sales. - **Pharmaceutical collaboration partners** (primary) — Large biopharma companies that pay upfront, milestone and reimbursement amounts to access HOOKIPA’s technology and programs. - **Government and grant funding sources** (secondary) — Public-sector programs that provide research incentives and non-dilutive funding to support development work. - **Future patients and healthcare providers** (emerging) — Patients and clinicians in HBV, HIV, oncology and other serious-disease areas that would use approved products if development succeeds. - Pharma collaboration partners funding platform and program development - Gilead for HBV and HIV vaccine research collaboration - Roche for collaboration revenue and milestone recognition - Future patients and physicians if product candidates are approved - Potential government grant providers supporting R&D ## Geography HOOKIPA is headquartered in the United States but has meaningful operational exposure to Austria, where it references local macroeconomic conditions and received Austrian government research incentives. Its business is globally connected through collaboration partners, third-party suppliers and clinical development activities, so trade policy, tariffs and foreign exchange conditions can affect costs and timelines. - United States is the corporate base and key capital market exposure - Austria is important for operations and government research incentives - Global supply chain dependence creates cross-border manufacturing risk - Third-party suppliers are located outside the United States - Trade restrictions can affect research materials and clinical supply ## Strategy The company’s near-term strategy is to advance current and future product candidates through preclinical and clinical development while seeking regulatory approvals where data support them. It also aims to secure additional financing and collaborations, build manufacturing access through third parties, and eventually create the commercial infrastructure needed for any approved products. - **Advance clinical and preclinical programs** (short-term) — Pipeline progress is the main value driver because the company has no product sales today. - **Secure non-dilutive and dilutive funding** (short-term) — The company expects continued losses and needs capital to avoid slowing or stopping development. - **Strengthen manufacturing and commercialization readiness** (medium-term) — Approved products would require reliable supply, quality control and a sales infrastructure. - Advance HBV, HIV and oncology programs through development stages - Use collaborations to fund R&D and extend platform reach - Seek regulatory approvals for candidates with acceptable risk-benefit - Build third-party or internal manufacturing capabilities - Preserve cash through financing, grants and disciplined spending ## Risks HOOKIPA faces classic clinical-stage biotech risks: program failure, delayed trials, regulatory setbacks and the need for substantial additional capital. It also has material exposure to trade policy, third-party manufacturing dependence and macroeconomic conditions that can affect funding access, supply chains and development costs. - **Insufficient financing** [high] — The company expects continued losses and says it will require substantial additional capital to continue programs. - **Clinical and regulatory failure** [high] — Product candidates must succeed in preclinical studies, clinical trials and regulatory review before any product revenue can begin. - **Third-party manufacturing dependence** [high] — HOOKIPA does not own or operate manufacturing facilities and relies on external suppliers and manufacturers. - **Trade policy and tariff exposure** [medium] — The company relies on a global supply chain and notes that tariffs and trade barriers could increase costs and delay development. - **Collaboration concentration** [high] — Current revenue is concentrated in a small number of collaboration agreements, so termination or non-renewal would materially reduce revenue. - Clinical trials may fail or produce weak efficacy or safety data - The company may not raise enough capital to fund development - Third-party manufacturing dependence can disrupt supply and timelines - Tariffs and trade restrictions can raise R&D and production costs - Collaboration terminations can remove major revenue sources ## Accounting Revenue recognition is highly judgmental because the company’s revenue comes from collaboration agreements, including upfront, milestone and reimbursement components that may be recognized over time or upon achievement of milestones. Investors should also watch deferred revenue roll-off, milestone timing, and estimates tied to research incentives, lease liabilities and other accruals that can move reported results materially from quarter to quarter. - **Collaboration revenue recognition** — Can create large quarter-to-quarter swings in revenue and earnings - **Deferred revenue** — Material effect on reported revenue and operating cash flow timing - **Research incentives and receivables** — Affects working capital and cash conversion - **Estimates and judgments** — Can affect asset, liability and expense recognition - Collaboration revenue depends on milestone and deferred revenue recognition - Revenue timing can shift sharply when agreements are terminated or amended - Research reimbursement and milestone invoicing affect receivables and cash flow - Austrian research incentives create receivable and cash timing differences - Lease, accrual and estimate judgments affect reported liabilities and expenses --- *Last updated: 2026-04-28T20:13:53.097477+00:00*